Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart
Initiation of Phase 1b study using SGT-212 for the treatment of patients with Friedreich's Ataxia expected in 2H25. Click ...
Zacks.com on MSN3mon
PTCT Stock Rises on Positive Updates on Friedreich Ataxia Program
A rare, physically debilitating, life-shortening, neuromuscular disorder, FA, mainly affects the central nervous system ...
Seeking Alpha26d
Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better
Friedreich's Ataxia [FA] is a disorder characterized as ... This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace.